PL3076971T3 - Kompozycje i sposoby ograniczania poważnych niepożądanych zdarzeń sercowo-naczyniowych - Google Patents

Kompozycje i sposoby ograniczania poważnych niepożądanych zdarzeń sercowo-naczyniowych

Info

Publication number
PL3076971T3
PL3076971T3 PL14867191T PL14867191T PL3076971T3 PL 3076971 T3 PL3076971 T3 PL 3076971T3 PL 14867191 T PL14867191 T PL 14867191T PL 14867191 T PL14867191 T PL 14867191T PL 3076971 T3 PL3076971 T3 PL 3076971T3
Authority
PL
Poland
Prior art keywords
compositions
methods
cardiovascular events
adverse cardiovascular
major adverse
Prior art date
Application number
PL14867191T
Other languages
English (en)
Inventor
Preston KLASSEN
Kristin Taylor
Original Assignee
Nalpropion Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52575014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3076971(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nalpropion Pharmaceuticals Llc filed Critical Nalpropion Pharmaceuticals Llc
Publication of PL3076971T3 publication Critical patent/PL3076971T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL14867191T 2013-12-06 2014-12-04 Kompozycje i sposoby ograniczania poważnych niepożądanych zdarzeń sercowo-naczyniowych PL3076971T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361913216P 2013-12-06 2013-12-06
US201361914938P 2013-12-11 2013-12-11
US201461984580P 2014-04-25 2014-04-25
US14/322,810 US8969371B1 (en) 2013-12-06 2014-07-02 Compositions and methods for weight loss in at risk patient populations
PCT/US2014/068527 WO2015085044A1 (en) 2013-12-06 2014-12-04 Compositions and methods for reducing major adverse cardiovascular events
EP14867191.0A EP3076971B1 (en) 2013-12-06 2014-12-04 Compositions and methods for reducing major adverse cardiovascular events

Publications (1)

Publication Number Publication Date
PL3076971T3 true PL3076971T3 (pl) 2022-04-04

Family

ID=52575014

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14867191T PL3076971T3 (pl) 2013-12-06 2014-12-04 Kompozycje i sposoby ograniczania poważnych niepożądanych zdarzeń sercowo-naczyniowych

Country Status (33)

Country Link
US (9) US8969371B1 (pl)
EP (2) EP4005571A1 (pl)
JP (2) JP6665094B2 (pl)
KR (3) KR102472432B1 (pl)
CN (3) CN105899210A (pl)
AU (1) AU2014360492A1 (pl)
BR (1) BR112016012755A2 (pl)
CA (1) CA2932127C (pl)
CL (1) CL2016001362A1 (pl)
CR (1) CR20160313A (pl)
CY (1) CY1125114T1 (pl)
DK (1) DK3076971T3 (pl)
EA (1) EA201690964A1 (pl)
EC (1) ECSP16057765A (pl)
ES (1) ES2903391T3 (pl)
HR (1) HRP20220058T1 (pl)
HU (1) HUE057551T2 (pl)
IL (3) IL300870A (pl)
JO (1) JOP20140344B1 (pl)
LT (1) LT3076971T (pl)
MX (2) MX389742B (pl)
PE (1) PE20161034A1 (pl)
PL (1) PL3076971T3 (pl)
PT (1) PT3076971T (pl)
RS (1) RS62846B1 (pl)
RU (1) RU2711638C2 (pl)
SG (1) SG10201808055QA (pl)
SI (1) SI3076971T1 (pl)
TN (1) TN2016000231A1 (pl)
TW (1) TWI661826B (pl)
UY (1) UY35864A (pl)
WO (1) WO2015085044A1 (pl)
ZA (1) ZA201603831B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
CA2875056C (en) * 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
BR112019002781A2 (pt) * 2016-08-11 2019-07-09 Huawei Tech Co Ltd método de comunicação sem fio, estação base e dispositivo terminal baseado em espectro não licenciado
EP4444417A1 (en) * 2021-12-09 2024-10-16 InCarda Therapeutics, Inc. Inhaled therapy for cardiac arrhythmia
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
IL58649A (en) 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
WO1983003197A1 (en) 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058272T3 (es) 1987-05-04 1994-11-01 Lilly Co Eli Fluoxetina util para el tratamiento de la diabetes.
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
AU3419995A (en) 1994-09-19 1996-04-09 Du Pont Merck Pharmaceutical Company, The Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
EP0828489A4 (en) 1996-03-13 2001-04-04 Univ Yale Smoking cessation treatments using naltrexone and related compounds
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
DK0934069T3 (da) 1996-05-07 2007-03-19 Pliva Istrazivanje I Razvoj D Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser
WO1998000130A2 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Anticonvulsant sulfamate derivatives useful in treating obesity
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
DE69811378T2 (de) 1997-10-03 2004-02-12 Cary Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
WO2001019321A2 (en) 1999-09-15 2001-03-22 Elan Pharmaceuticals, Inc. Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
KR20020081271A (ko) 2000-01-22 2002-10-26 알버트 슐만 물질 남용의 치료 방법
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
EP1326630B1 (en) 2000-09-18 2008-05-28 Sanos Bioscience A/S Use of glp-2 peptides
EP1392250A2 (en) 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
BR0212019A (pt) 2001-08-06 2005-08-09 Euro Celtique Sa Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
EP1505974B1 (en) 2002-05-17 2009-04-22 Tioga Pharmaceuticals, Inc. Use of compounds that are effective as selective opiate receptor modulators
WO2003097046A1 (en) 2002-05-17 2003-11-27 Duke University Method for treating obesity
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
AU2003283958A1 (en) 2002-09-13 2004-04-30 Elan Pharmaceuticals, Inc. Method of treating tremors
US20040192715A1 (en) 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
EP1613324A2 (en) 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
EP1633400A2 (en) 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
WO2004110375A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of diabetes
JP4758897B2 (ja) 2003-09-25 2011-08-31 ユーロ−セルティーク エス．エイ． ヒドロコドンとナルトレキソンとの併用医薬
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20050277579A1 (en) 2004-05-03 2005-12-15 Ranga Krishnan Compositions for affecting weight loss
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
KR20070083534A (ko) 2004-08-03 2007-08-24 오렉시젠 세러퓨틱스 인크. 체중감량을 위한 부프로피온과 제2화합물의 조합
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2007064586A1 (en) 2005-11-28 2007-06-07 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
EP2061448B1 (en) 2006-06-05 2019-07-17 Nalpropion Pharmaceuticals, Inc. Sustained release formulation of naltrexone
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
EP2089005B1 (en) * 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP6196041B2 (ja) * 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
TW201735912A (zh) 2010-12-03 2017-10-16 歐瑞根治療有限公司 降低暴食或強迫進食之方法
CA2875056C (en) * 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
TW201607536A (zh) 2016-03-01
US10828294B2 (en) 2020-11-10
RS62846B1 (sr) 2022-02-28
SG10201808055QA (en) 2018-10-30
AU2014360492A1 (en) 2016-06-23
CY1125114T1 (el) 2023-06-09
CN105899210A (zh) 2016-08-24
MX389742B (es) 2025-03-20
JP2020037593A (ja) 2020-03-12
US20150366860A1 (en) 2015-12-24
IL245919A0 (en) 2016-07-31
MX2022001251A (es) 2022-02-23
IL300870A (en) 2023-04-01
US9801875B2 (en) 2017-10-31
US8969371B1 (en) 2015-03-03
ZA201603831B (en) 2023-05-31
US20190374535A1 (en) 2019-12-12
RU2711638C2 (ru) 2020-01-17
KR20230152800A (ko) 2023-11-03
CN114404419A (zh) 2022-04-29
KR20220165791A (ko) 2022-12-15
US10231962B2 (en) 2019-03-19
ECSP16057765A (es) 2017-02-24
US10835527B2 (en) 2020-11-17
US10231964B2 (en) 2019-03-19
US20250144089A1 (en) 2025-05-08
EP3076971A4 (en) 2017-06-28
EP3076971A1 (en) 2016-10-12
CL2016001362A1 (es) 2017-01-06
KR102472432B1 (ko) 2022-11-30
BR112016012755A2 (pt) 2017-08-08
KR20160095076A (ko) 2016-08-10
JP6665094B2 (ja) 2020-03-13
EP4005571A1 (en) 2022-06-01
WO2015085044A1 (en) 2015-06-11
US20210069181A1 (en) 2021-03-11
TWI661826B (zh) 2019-06-11
EP3076971B1 (en) 2021-10-20
IL282117A (en) 2021-05-31
ES2903391T3 (es) 2022-04-01
NZ720620A (en) 2022-03-25
JP7204634B2 (ja) 2023-01-16
PT3076971T (pt) 2022-01-26
US20190314363A1 (en) 2019-10-17
CA2932127C (en) 2023-05-02
MX2016007231A (es) 2016-08-04
TN2016000231A1 (en) 2017-10-06
CA2932127A1 (en) 2015-06-11
JOP20140344B1 (ar) 2021-08-17
JP2016539164A (ja) 2016-12-15
LT3076971T (lt) 2022-02-10
US9119850B2 (en) 2015-09-01
US20180243288A1 (en) 2018-08-30
PE20161034A1 (es) 2016-11-13
EA201690964A1 (ru) 2016-12-30
US20160310485A1 (en) 2016-10-27
US11998542B2 (en) 2024-06-04
UY35864A (es) 2015-07-31
DK3076971T3 (da) 2022-01-24
US20150182524A1 (en) 2015-07-02
HRP20220058T1 (hr) 2022-04-15
CN117159547A (zh) 2023-12-05
HUE057551T2 (hu) 2022-05-28
CR20160313A (es) 2018-01-26
SI3076971T1 (sl) 2022-04-29

Similar Documents

Publication Publication Date Title
IL282117A (en) Preparations and methods for reducing serious cardiovascular events
IL289821A (en) Preparations and methods for immunotherapy
IL273205A (en) Preparations and methods
GB2521022B (en) Compositions and methods
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
GB201308072D0 (en) Compositions and methods
SG11201507688VA (en) Compositions and methods for immunotherapy
EP2970673A4 (en) BINDER COMPOSITIONS AND METHODS OF MAKING AND USING THEM
EP2970734A4 (en) COMPOSITIONS AND METHOD OF REFRIGERATION
GB201305414D0 (en) Method and composition
IL243235A0 (en) Preparations and methods for immunotherapy
EP2966975A4 (en) POLLINATION ENHANCEMENT COMPOSITIONS AND METHOD FOR THEIR USE
GB201305813D0 (en) Compositions and methods
IL239680A0 (en) Preparations and methods for polynucleotide transfection
PL3019024T3 (pl) Kompozycje i sposoby do zwiększania wydolności podczas wysiłku fizycznego
ZA201506873B (en) Binder compositions and methods for making and using same
GB201322456D0 (en) Radiotracer compositions and methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
SG11201604904XA (en) Detergent and rinse-aid compositions and methods
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods